Get the Stockscreener App
11.17
0.18%
-0.02
After Hours:
11.26
0.09
+0.81%
Moonlake Immunotherapeutics stock is traded at $11.17, with a volume of 1.61M.
It is down -0.18% in the last 24 hours and down -25.03% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$11.19
Open:
$11.28
24h Volume:
1.61M
Relative Volume:
0.51
Market Cap:
$791.37M
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-4.8565
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-15.44%
1M Performance:
-25.03%
6M Performance:
-77.15%
1Y Performance:
-78.42%
1-Day Range:
$11.10
$11.70
1-Week Range:
$11.06
$13.32
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
11.17 | 792.78M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3%Time to Sell? - MarketBeat
(MLTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Responsive Playbooks and the MLTX Inflection - Stock Traders Daily
Why MoonLake Immunotherapeutics stock could rally in 2025Long Setup & Smart Investment Allocation Insights - Улправда
Trend Report: Will MoonLake Immunotherapeutics stock gain from strong economyWeekly Trade Analysis & Risk Managed Trade Strategies - Улправда
Will MoonLake Immunotherapeutics stock rally after Fed decisionsEarnings Beat & Free Reliable Trade Execution Plans - Улправда
Can MoonLake Immunotherapeutics stock hit analyst price targetsJuly 2025 Update & Weekly High Momentum Picks - Улправда
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research - MSN
Is MoonLake Immunotherapeutics stock attractive for income investorsMarket Risk Analysis & Real-Time Volume Analysis Alerts - Bölüm Sonu Canavarı
MoonLake Extends Sonelokimab Data in Psoriatic Arthritis: What Investors Should Watch - TipRanks
Will MoonLake Immunotherapeutics stock reach all time highs in 2025 - DonanımHaber
Can MoonLake Immunotherapeutics stock hit record highs againWeekly Trade Summary & Risk Controlled Daily Trade Plans - DonanımHaber
Panic Selling: Will MoonLake Immunotherapeutics stock gain from strong economy2025 Momentum Check & Real-Time Price Movement Reports - Улправда
Can MoonLake Immunotherapeutics stock sustain free cash flow growth2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
How buybacks impact MoonLake Immunotherapeutics stock valueTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 - ACCESS Newswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.7%Should You Sell? - MarketBeat
Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 - ACCESS Newswire
Contact Levi & Korsinsky by December 15, 2025 Deadline to - GlobeNewswire
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Invest - GuruFocus
2025-12-15 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025Contact Levi & Korsinsky | NDAQ:MLTX | Press Release - Stockhouse
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - marketscreener.com
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – MLTX - marketscreener.com
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX - GuruFocus
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Rutland Herald
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
2025-12-14 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (MLTX) Valuation After Sonelokimab Phase 3 Setback and Emerging Lawsuits - simplywall.st
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of MoonLake Immunotherapeutics to Contact the Firm Today! - ACCESS Newswire
MLTX DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit - TMX Newsfile
2025-12-14 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX SECURITIES LAWSUIT: MoonLake Immunotherapeutics Investors Are Notified to Contact BFA Law Before Tomorrow's December 15 Class Action Deadline - marketscreener.com
2025-12-13 | Class Action Lawsuit Alert: Levi & Korsinsky Reminds MoonLake Immunotherapeutics (MLTX) Investors of December 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6%Still a Buy? - MarketBeat
Phase 3 Miss and Fraud Suits Could Be A Game Changer For MoonLake Immunotherapeutics (MLTX) - simplywall.st
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action - GlobeNewswire
MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms - GlobeNewswire Inc.
MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the - GuruFocus
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics - GlobeNewswire
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):